A Phase Ib Safety and Pharmacokinetics (PK)/ Pharmacodynamics (PD) Study to Determine the Dosage of Abraxane in Combination with Phenelzine Sulfate in Metastatic or Inoperable Locally Advanced Breast Cancer

Trial Profile

A Phase Ib Safety and Pharmacokinetics (PK)/ Pharmacodynamics (PD) Study to Determine the Dosage of Abraxane in Combination with Phenelzine Sulfate in Metastatic or Inoperable Locally Advanced Breast Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs Paclitaxel (Primary) ; Phenelzine (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Proof of concept
  • Acronyms Epi-PRIMED
  • Sponsors EpiAxis Therapeutics
  • Most Recent Events

    • 15 Jan 2018 Planned End Date changed from 25 Sep 2018 to 1 Mar 2019.
    • 15 Jan 2018 Status changed from not yet recruiting to recruiting.
    • 01 Oct 2017 According to an EpiAxis Therapeutics medis release, first patient has been recruited.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top